🇺🇸 "Priming" dose of ribavirin given in United States

3,430 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 511 reports (14.9%)
  2. Macular Degeneration — 451 reports (13.15%)
  3. Off Label Use — 449 reports (13.09%)
  4. Pyrexia — 422 reports (12.3%)
  5. Nausea — 306 reports (8.92%)
  6. Pain — 288 reports (8.4%)
  7. Malaise — 272 reports (7.93%)
  8. Cytokine Release Syndrome — 268 reports (7.81%)
  9. Weight Decreased — 235 reports (6.85%)
  10. Constipation — 228 reports (6.65%)

Source database →

Other Virology/Infectious Disease approved in United States

Frequently asked questions

Is "Priming" dose of ribavirin given approved in United States?

"Priming" dose of ribavirin given does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for "Priming" dose of ribavirin given in United States?

Göteborg University is the originator. The local marketing authorisation holder may differ — check the official source linked above.